久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Inovio reports positive data from Phase II Covid-19 DNA vaccine trial pharmaceutical-technology
    May 12, 2021
    The Inovio vaccine Phase II trial assessed the safety, tolerability and immunogenicity of two doses of INO-4800 to detect optimal dose(s) for age groups, namely 18 to 50 years and 51 years and above, for the Phase III efficacy analysis.
PharmaSources Customer Service